Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585150 · ClinicalTrials.gov registry record · Phase 2
Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT06585150 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 150 participants.
The verdict
NCT06585150, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study were to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Interventions
- DRUG Obeldesivir
- DRUG Obeldesivir Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2025-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06585150
The ClinicalTrials.gov registry entry for NCT06585150 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Obeldesivir is the first listed.
NCT06585150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06585150 about?
NCT06585150 is a clinical study titled "Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection". The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptom...
What is the current status of trial NCT06585150?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-10-14. Estimated completion is 2025-06-09.
What interventions are being tested in trial NCT06585150?
The interventions under investigation include: Obeldesivir (DRUG), Obeldesivir Placebo (DRUG).
Who is sponsoring clinical trial NCT06585150?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.